SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 82 of 83
Word Count: 561
Character Count: 3591

Document Content:

is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. 7. The undersigned registrant hereby undertakes that: a. For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

b.	For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.

SIGNATURES

Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the Town of Mansfield, Commonwealth of Massachusetts, on February 12, 2026.

BioVentrix,
Inc.

David Richmond

Name:	David
Richmond

Title:	Co-Chief
Executive Officer

POWER
OF ATTORNEY

KNOW
ALL BY THESE PRESENT, that each person whose signature appears below constitutes and appoints each of David Richmond and Steven
Chartier, severally, as his true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in
his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including
post-effective amendments), and to sign any registration statement for the same offering covered by this registration statement that
is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto,
and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could
do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully
do or cause to be done by virtue hereof.

Pursuant
to the requirements of the Securities Act, this registration statement has been signed below by the following persons in the capacities
and on the dates indicated.

Signature Title Date

David Richmond Chairman
of the Board, Co-Chief Executive Officer and Chief Financial Officer February

David
Richmond (Principal
Executive Officer, Principal Accounting Officer and Principal Financial Officer)

Steven Chartier Co-Chief
Executive Officer, President and Director February

Steven
Chartier

/s/ Mark Ravich Director February 12, 2026

Mark Ravich

/s/ Rishi Puri Director February 12, 2026

Rishi Puri

/s/ William Abraham Director February 12, 2026

William Abraham